TYK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL95630	0.65	8/20
SCHEMBL98880	0.51	7/20
SCHEMBL100598	0.67	6/20
SCHEMBL101975	0.62	6/20
SCHEMBL101614	0.59	6/20
SCHEMBL98964	0.57	6/20
SCHEMBL98856	0.56	6/20
SCHEMBL100168	0.55	6/20
SCHEMBL100599	0.55	6/20
SCHEMBL100772	0.55	6/20
SCHEMBL99163	0.55	6/20
SCHEMBL100486	0.55	6/20
SCHEMBL101518	0.55	6/20
SCHEMBL99503	0.53	6/20
SCHEMBL99812	0.53	6/20
SCHEMBL101611	0.52	6/20
SCHEMBL98901	0.51	6/20
SCHEMBL101325	0.51	6/20
SCHEMBL101326	0.51	6/20
SCHEMBL100309	0.77	5/20

Clinical trials — most relevant to TYK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Correction of Psoriatic T Cell Signatures by Deucravacitinib	PHASE4	RECRUITING
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis	PHASE4	NOT_YET_RECRUITING
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus	PHASE3	RECRUITING
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy	PHASE3	ACTIVE_NOT_RECRUITING
Deucravacitinib in the Treatment of Cicatricial Alopecias	PHASE2	RECRUITING
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia	PHASE2	COMPLETED
Deucravacitinib Rosacea	PHASE2	WITHDRAWN
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris	PHASE2	COMPLETED
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis	PHASE2	WITHDRAWN
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	PHASE2	UNKNOWN
Tyrosine Kinase 2 (TYK2) for GA and CS	PHASE2	WITHDRAWN
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris	PHASE2	RECRUITING
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.	PHASE2	COMPLETED
Ritlecitinib for Cicatricial Alopecia	PHASE2	COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
Safety and Pharmacokinetic Study of ARTS-011 in Chinese Healthy Volunteers	PHASE1	COMPLETED
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease	PHASE1	RECRUITING
A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults	PHASE1	COMPLETED
A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers	PHASE1	COMPLETED
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants	PHASE1	COMPLETED
A Target Occupancy Study With Ritlecitinib.	PHASE1	COMPLETED
A Study of TYK-00540 in Adult Patients With Solid Tumors	PHASE1	RECRUITING
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis	nan	RECRUITING
Cutaneous JAK in Vitiligo and Acne Vulgaris.	nan	UNKNOWN
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo	nan	UNKNOWN
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)	nan	RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
Risk Factor Analysis for Charcot Foot in Patients With Diabetes Mellitus: The Interplay of Inflammatory Cytokines and Metabolic Factors	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a TYK2 binder may also engage these)

Protein	Name	Similarity
Q9R117	—	1.000	Q9R117 →
JAK3	Tyrosine-protein kinase JAK3	1.000	landscape →
Q63272	—	0.998	Q63272 →
Q62137	—	0.995	Q62137 →
D3ZEY4	—	0.994	D3ZEY4 →
Q9Y4C4	—	0.993	Q9Y4C4 →
Q8TDY4	—	0.993	Q8TDY4 →
Q6XUX1	—	0.993	Q6XUX1 →
Q8TBC3	—	0.993	Q8TBC3 →
D3YWQ0	—	0.993	D3YWQ0 →
Q8VCC8	—	0.992	Q8VCC8 →
Q09178	—	0.992	Q09178 →
Q4TVR5	—	0.992	Q4TVR5 →
Q4VSN4	—	0.992	Q4VSN4 →
A2CI34	—	0.992	A2CI34 →
A3KMV1	—	0.992	A3KMV1 →
Q6P5E8	—	0.991	Q6P5E8 →
O75064	—	0.991	O75064 →
O12990	—	0.991	O12990 →
P35546	—	0.991	P35546 →
Q3U1Y4	—	0.990	Q3U1Y4 →
RAPGEF3	Rap guanine nucleotide exchange factor 3	0.990	landscape →
Q28314	—	0.990	Q28314 →
Q95KV0	—	0.990	Q95KV0 →
Q4VSN3	—	0.990	Q4VSN3 →
Q3ULB5	—	0.990	Q3ULB5 →
Q9NSY0	—	0.990	Q9NSY0 →
Q00495	—	0.989	Q00495 →
Q8K330	—	0.989	Q8K330 →
Q9Z1C8	—	0.989	Q9Z1C8 →